BioMarin Pharmaceutical Inc. $BMRN Stake Cut by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 66.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 344,138 shares of the biotechnology company’s stock after selling 695,346 shares during the quarter. Assenagon Asset Management S.A. owned 0.18% of BioMarin Pharmaceutical worth $18,639,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Dodge & Cox lifted its position in BioMarin Pharmaceutical by 1.0% in the 2nd quarter. Dodge & Cox now owns 15,108,310 shares of the biotechnology company’s stock worth $830,504,000 after buying an additional 153,070 shares in the last quarter. Viking Global Investors LP increased its stake in shares of BioMarin Pharmaceutical by 13.8% in the second quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after acquiring an additional 1,488,552 shares during the last quarter. AQR Capital Management LLC raised its holdings in shares of BioMarin Pharmaceutical by 90.7% during the second quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock worth $306,429,000 after acquiring an additional 2,654,768 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of BioMarin Pharmaceutical by 1.3% during the second quarter. Geode Capital Management LLC now owns 3,474,438 shares of the biotechnology company’s stock worth $190,417,000 after acquiring an additional 43,185 shares in the last quarter. Finally, Norges Bank acquired a new stake in BioMarin Pharmaceutical during the second quarter valued at $112,352,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN opened at $61.15 on Friday. The stock has a 50-day simple moving average of $53.67 and a 200 day simple moving average of $55.62. BioMarin Pharmaceutical Inc. has a twelve month low of $50.76 and a twelve month high of $73.51. The stock has a market capitalization of $11.75 billion, a PE ratio of 22.99, a P/E/G ratio of 0.87 and a beta of 0.30. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.10 and a current ratio of 4.83.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Monday, October 27th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.20). BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The business had revenue of $776.13 million during the quarter, compared to the consensus estimate of $782.42 million. During the same period in the prior year, the firm earned $0.91 earnings per share. The business’s quarterly revenue was up 4.1% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. Research analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Strategic, revenue-accretive acquisition: BioMarin will pay ~$4.8B to buy Amicus, adding marketed drugs (Galafold for Fabry; Pombiliti + Opfolda for Pompe) and management projects the deal will accelerate revenue growth and be accretive to non‑GAAP EPS within 12 months. PR Newswire
• Positive Sentiment: Immediate revenue contribution: The acquired brands generated roughly $599M in the past four quarters, providing near-term top-line lift and diversification of BioMarin’s marketed portfolio. BioSpace
• Positive Sentiment: Patent/litigation clarity cited: Company commentary indicates resolution of pending U.S. patent litigation around Galafold will accelerate revenue post-close, reducing a key uncertainty. PR Newswire
• Positive Sentiment: Analyst / market support: Analysts are framing the deal as strategic; Wedbush maintained a Buy and $94 price target, and several outlets highlight strong investor enthusiasm. Unusual options activity — a big increase in calls — underscores bullish positioning. TipRanks
• Neutral Sentiment: Market reaction / volume and calls: Heavy trading and a surge in call buying indicate speculative and directional interest; follow-through will depend on deal close and integration updates. (No direct link)
• Neutral Sentiment: Management investor call: BioMarin held an M&A call to discuss deal rationale and timing — listen for close timing, expected synergies and integration plans. Seeking Alpha transcript
• Negative Sentiment: Cash/financing and integration risks: The all-cash $4.8B price is sizable — potential pressure on liquidity or need for financing, and integration/execution risk could weigh if synergies are slower than expected. Reuters
• Negative Sentiment: Valuation / execution risk: Investors will scrutinize the price paid vs. long-term upside — overpaying or missed sales recovery for acquired brands would reverse some of the positive reaction. WSJ

Wall Street Analyst Weigh In

Several research analysts have weighed in on BMRN shares. Tudor Pickering set a $88.00 target price on BioMarin Pharmaceutical in a research report on Monday, November 3rd. Weiss Ratings reiterated a “sell (d)” rating on shares of BioMarin Pharmaceutical in a report on Monday. HC Wainwright dropped their price objective on BioMarin Pharmaceutical from $60.00 to $55.00 and set a “neutral” rating on the stock in a report on Monday, October 27th. Barclays cut their price objective on shares of BioMarin Pharmaceutical from $86.00 to $80.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 28th. Finally, Raymond James Financial assumed coverage on shares of BioMarin Pharmaceutical in a research report on Wednesday, September 3rd. They issued an “outperform” rating and a $85.00 target price for the company. Sixteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.61.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.